Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wisniacki

Showing results (61-70 of 73) with videos related to

Pageof 8
Sort By:
Acta Gastroenterologica Latinoamericana|December 4, 2025
[Partial External Biliary Diversion in Progressive Familial Intrahepatic Cholestasis and Alagille Syndrome: A Case Series]Fabian Salgueiro, Carol Lezama Elecharri, Marcela Galoppo, et al.
Diabetologia|November 4, 2020
A randomised, single-blind, placebo-controlled, dose-finding safety and tolerability study of the anti-CD3 monoclonal antibody otelixizumab in new-onset type 1 diabetesBart Keymeulen, André van Maurik, Dave Inman, et al.
The Lancet. Rheumatology|November 21, 2022
Integrated analysis of dermal blister fluid proteomics and genome-wide skin gene expression in systemic sclerosis: an observational studyKristina E N Clark, Eszter Csomor, Corrado Campochiaro, et al.
Annals of the Rheumatic Diseases|July 7, 2021
Molecular basis for clinical diversity between autoantibody subsets in diffuse cutaneous systemic sclerosisKristina Elizabeth Neergaard Clark, Corrado Campochiaro, Eszter Csomor, et al.
Rheumatology (Oxford, England)|May 18, 2022
Biological and clinical insights from a randomized phase 2 study of an anti-oncostatin M monoclonal antibody in systemic sclerosisChristopher P Denton, Francesco Del Galdo, Dinesh Khanna, et al.
EJNMMI Research|December 21, 2019
Quantifying disease activity in rheumatoid arthritis with the TSPO PET ligand <sup>18</sup>F-GE-180 and comparison with <sup>18</sup>F-FDG and DCE-MRIMarius de Groot, Neel Patel, Roido Manavaki, et al.
Magnetic Resonance Imaging|June 30, 2015
Towards the identification of multi-parametric quantitative MRI biomarkers in lupus nephritisStanislas Rapacchi, Robert X Smith, Yi Wang, et al.
JCI Insight|December 8, 2022
A randomized, phase II study of sequential belimumab and rituximab in primary Sjögren's syndromeXavier Mariette, Francesca Barone, Chiara Baldini, et al.
Rheumatology (Oxford, England)|November 22, 2020
Advanced imaging for quantification of abnormalities in the salivary glands of patients with primary Sjögren's syndromePilar Jimenez-Royo, Michele Bombardieri, Coziana Ciurtin, et al.
Annals of the Rheumatic Diseases|October 17, 2024
Efficacy, safety and tolerability of GSK3858279, an anti-CCL17 monoclonal antibody and analgesic, in healthy volunteers and patients with knee osteoarthritis pain: a phase I, randomised, double-blind, placebo-controlled, proof-of-mechanism and proof-of-concept studyJagtar Singh Nijjar, Katharine Abbott-Banner, Yolanda Alvarez, et al.
Pageof 8

Showing results (61-70 of 73) with videos related to

Sort By:
Pageof 8
Acta Gastroenterologica Latinoamericana|December 4, 2025
[Partial External Biliary Diversion in Progressive Familial Intrahepatic Cholestasis and Alagille Syndrome: A Case Series]Fabian Salgueiro, Carol Lezama Elecharri, Marcela Galoppo, et al.
Diabetologia|November 4, 2020
A randomised, single-blind, placebo-controlled, dose-finding safety and tolerability study of the anti-CD3 monoclonal antibody otelixizumab in new-onset type 1 diabetesBart Keymeulen, André van Maurik, Dave Inman, et al.
The Lancet. Rheumatology|November 21, 2022
Integrated analysis of dermal blister fluid proteomics and genome-wide skin gene expression in systemic sclerosis: an observational studyKristina E N Clark, Eszter Csomor, Corrado Campochiaro, et al.
Annals of the Rheumatic Diseases|July 7, 2021
Molecular basis for clinical diversity between autoantibody subsets in diffuse cutaneous systemic sclerosisKristina Elizabeth Neergaard Clark, Corrado Campochiaro, Eszter Csomor, et al.
Rheumatology (Oxford, England)|May 18, 2022
Biological and clinical insights from a randomized phase 2 study of an anti-oncostatin M monoclonal antibody in systemic sclerosisChristopher P Denton, Francesco Del Galdo, Dinesh Khanna, et al.
EJNMMI Research|December 21, 2019
Quantifying disease activity in rheumatoid arthritis with the TSPO PET ligand <sup>18</sup>F-GE-180 and comparison with <sup>18</sup>F-FDG and DCE-MRIMarius de Groot, Neel Patel, Roido Manavaki, et al.
Magnetic Resonance Imaging|June 30, 2015
Towards the identification of multi-parametric quantitative MRI biomarkers in lupus nephritisStanislas Rapacchi, Robert X Smith, Yi Wang, et al.
JCI Insight|December 8, 2022
A randomized, phase II study of sequential belimumab and rituximab in primary Sjögren's syndromeXavier Mariette, Francesca Barone, Chiara Baldini, et al.
Rheumatology (Oxford, England)|November 22, 2020
Advanced imaging for quantification of abnormalities in the salivary glands of patients with primary Sjögren's syndromePilar Jimenez-Royo, Michele Bombardieri, Coziana Ciurtin, et al.
Annals of the Rheumatic Diseases|October 17, 2024
Efficacy, safety and tolerability of GSK3858279, an anti-CCL17 monoclonal antibody and analgesic, in healthy volunteers and patients with knee osteoarthritis pain: a phase I, randomised, double-blind, placebo-controlled, proof-of-mechanism and proof-of-concept studyJagtar Singh Nijjar, Katharine Abbott-Banner, Yolanda Alvarez, et al.
Pageof 8